Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL).

MLA

McDonald, A., et al. “Phase 2 KEYNOTE‐B68 Study: Pembrolizumab Every 6 Weeks in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (CHL) or Primary Mediastinal B‐cell Lymphoma (PMBCL).” Hematological Oncology, vol. 41, June 2023, pp. 575–77. EBSCOhost, https://doi.org/10.1002/hon.3164_431.

APA

McDonald, A., Verburgh, E., Gotti, M., Pinto, A., Zaucha, J., Ivanov, V., Melnichenko, V., Mocikova, H., Ozcan, M., Patti, C., Farias, J., Goncalves, I., Kuchkova, O., Mayer, J., Saydam, G., Tomassetti, S., Pathiraja, K., Ryland, K., Chakraborty, S., & Jurczak, W. (2023). Phase 2 KEYNOTE‐B68 study: pembrolizumab every 6 weeks in relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL) or primary mediastinal B‐cell lymphoma (PMBCL). Hematological Oncology, 41, 575–577. https://doi.org/10.1002/hon.3164_431

Chicago

McDonald, A., E. Verburgh, M. Gotti, A. Pinto, J. Zaucha, V. Ivanov, V. Melnichenko, et al. 2023. “Phase 2 KEYNOTE‐B68 Study: Pembrolizumab Every 6 Weeks in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (CHL) or Primary Mediastinal B‐cell Lymphoma (PMBCL).” Hematological Oncology 41 (June): 575–77. doi:10.1002/hon.3164_431.